STOCK TITAN

Nano-X (NNOX) director sells 678 shares to cover RSU tax

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Nano-X Imaging Ltd. director Alroy Erez sold 678 ordinary shares on June 10, 2026 at $1.65 per share in open-market transactions. A footnote explains that the reported sale of ordinary shares was used to cover tax liabilities arising from the vesting of restricted share units.

Following these transactions, Erez continues to hold ordinary shares tied to RSU grants, including 6,753 and 17,075 ordinary shares remaining or issuable under two separate awards. He also holds stock options over 10,000 ordinary shares at an exercise price of $11.52 expiring on December 31, 2033, and options over 50,000 ordinary shares at an exercise price of $17.63 expiring on December 28, 2032.

Positive

  • None.

Negative

  • None.
Insider Alroy Erez
Role null
Sold 678 shs ($1K)
Type Security Shares Price Value
Sale Ordinary Shares 209 $1.65 $344.85
Sale Ordinary Shares 469 $1.65 $773.85
holding Stock Option (right to buy ordinary shares) -- -- --
holding Stock Option (right to buy ordinary shares) -- -- --
Holdings After Transaction: Ordinary Shares — 6,753 shares (Direct, null); Stock Option (right to buy ordinary shares) — 50,000 shares (Direct, null)
Footnotes (1)
  1. The transaction reported in this row involved the sale of ordinary shares to cover tax liabilities arising from the vesting of restricted share units ("RSUs"). The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person by the Issuer that began vesting on December 10, 2024. Currently, 6,753 ordinary shares constitute the remainder of the ordinary shares held by, or issuable to, the Reporting Person under the subject grant. The 7,792 RSUs originally granted vest (and settle for underlying ordinary shares) on an equal, quarterly basis over twelve calendar quarters (for 649.33 underlying ordinary shares per quarter) such that all such 7,792 RSUs - reduced by RSUs for which underlying shares have been sold to cover tax liability - will be vested by December 10, 2027. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person by the Issuer that began vesting on December 10, 2025. Currently, 17,075 ordinary shares constitute the remainder of the ordinary shares held by, or issuable to, the Reporting Person under the subject grant. The 17,544 RSUs originally granted vest (and settle for underlying ordinary shares) on an equal, quarterly basis over twelve calendar quarters (for 1,462 underlying ordinary shares per quarter) such that all such 17,544 RSUs - reduced by RSUs for which underlying shares have been sold to cover tax liability - will be vested by December 10, 2028. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. The options reported in this row were granted to the Reporting Person by the Issuer on December 28, 2022 and vest and become exercisable in 16 equal quarterly installments of 6.25% each on each three-month anniversary of the date of appointment of the Reporting Person to the Issuer's Board of Directors on June 30, 2022, such that all options reported in this row will be exercisable by the four-year anniversary of that appointment date (June 30, 2026). The options reported in this row were granted to the Reporting Person by the Issuer on December 31, 2023 and vest and become exercisable in 16 equal quarterly installments of 6.25% each on each three-month anniversary of the date of approval of the grant by the Issuer's Board of Directors (i.e., August 14, 2023), such that all options reported in this row will be exercisable by the four-year anniversary of that grant approval date (August 14, 2027).
Shares sold 678 shares Ordinary shares sold on June 10, 2026 at $1.65
Sale price $1.65 per share Open-market sale of 678 ordinary shares
Remaining RSU-related shares (grant 1) 6,753 ordinary shares Remainder held by or issuable to Erez under RSU grant beginning December 10, 2024
Remaining RSU-related shares (grant 2) 17,075 ordinary shares Remainder held by or issuable to Erez under RSU grant beginning December 10, 2025
Option position 1 10,000 shares at $11.52 Stock options over ordinary shares expiring December 31, 2033
Option position 2 50,000 shares at $17.63 Stock options over ordinary shares expiring December 28, 2032
Original RSU grant 1 7,792 RSUs Vesting quarterly over twelve quarters to be fully vested by December 10, 2027
Original RSU grant 2 17,544 RSUs Vesting quarterly over twelve quarters to be fully vested by December 10, 2028
restricted share units ("RSUs") financial
"sale of ordinary shares to cover tax liabilities arising from the vesting of restricted share units ("RSUs")."
open-market sale financial
"transaction_action": "open-market sale", "transaction_code_description": "Sale in open market or private transaction""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Stock Option (right to buy ordinary shares) financial
"security_title": "Stock Option (right to buy ordinary shares)""
vesting financial
"RSUs originally granted vest (and settle for underlying ordinary shares) on an equal, quarterly basis"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
exercise price financial
"exercisePrice": "11.5200" and "17.6300" for stock options over ordinary shares"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Alroy Erez

(Last)(First)(Middle)
C/O NANO-X IMAGING LTD., OFER TECH PARK
94 SHLOMO SHMELTZER ROAD

(Street)
PETACH TIKVA4970602

(City)(State)(Zip)

ISRAEL

(Country)
2. Issuer Name and Ticker or Trading Symbol
Nano-X Imaging Ltd. [ NNOX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares06/10/2026S(1)209D$1.656,753(2)D
Ordinary Shares06/10/2026S(1)469D$1.6517,075(3)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy ordinary shares)(4)$17.63 (5)12/28/2032Ordinary Shares50,00050,000D
Stock Option (right to buy ordinary shares)(4)$11.52 (6)12/31/2033Ordinary Shares10,00010,000D
Explanation of Responses:
1. The transaction reported in this row involved the sale of ordinary shares to cover tax liabilities arising from the vesting of restricted share units ("RSUs").
2. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person by the Issuer that began vesting on December 10, 2024. Currently, 6,753 ordinary shares constitute the remainder of the ordinary shares held by, or issuable to, the Reporting Person under the subject grant. The 7,792 RSUs originally granted vest (and settle for underlying ordinary shares) on an equal, quarterly basis over twelve calendar quarters (for 649.33 underlying ordinary shares per quarter) such that all such 7,792 RSUs - reduced by RSUs for which underlying shares have been sold to cover tax liability - will be vested by December 10, 2027.
3. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person by the Issuer that began vesting on December 10, 2025. Currently, 17,075 ordinary shares constitute the remainder of the ordinary shares held by, or issuable to, the Reporting Person under the subject grant. The 17,544 RSUs originally granted vest (and settle for underlying ordinary shares) on an equal, quarterly basis over twelve calendar quarters (for 1,462 underlying ordinary shares per quarter) such that all such 17,544 RSUs - reduced by RSUs for which underlying shares have been sold to cover tax liability - will be vested by December 10, 2028.
4. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
5. The options reported in this row were granted to the Reporting Person by the Issuer on December 28, 2022 and vest and become exercisable in 16 equal quarterly installments of 6.25% each on each three-month anniversary of the date of appointment of the Reporting Person to the Issuer's Board of Directors on June 30, 2022, such that all options reported in this row will be exercisable by the four-year anniversary of that appointment date (June 30, 2026).
6. The options reported in this row were granted to the Reporting Person by the Issuer on December 31, 2023 and vest and become exercisable in 16 equal quarterly installments of 6.25% each on each three-month anniversary of the date of approval of the grant by the Issuer's Board of Directors (i.e., August 14, 2023), such that all options reported in this row will be exercisable by the four-year anniversary of that grant approval date (August 14, 2027).
/s/ Marina Gofman Feler, attorney-in-fact06/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Nano-X Imaging (NNOX) director Alroy Erez report in this Form 4?

Alroy Erez reported selling 678 ordinary shares of Nano-X Imaging on June 10, 2026 at $1.65 per share. The activity is disclosed as open-market sales with related details on his remaining share and option holdings.

At what price were the Nano-X Imaging (NNOX) shares sold by Alroy Erez?

The filing shows Erez’s sales of Nano-X Imaging ordinary shares at $1.65 per share. These open-market transactions totaled 678 shares and are associated with tax liabilities from restricted share unit vesting, according to the accompanying footnote.

How many Nano-X Imaging (NNOX) shares does Alroy Erez still hold from RSU grants?

The filing states that Erez has 6,753 ordinary shares remaining or issuable under one RSU grant and 17,075 ordinary shares remaining or issuable under another, reflecting continuing equity exposure from these multi-year vesting awards.

What stock options over Nano-X Imaging (NNOX) shares does Alroy Erez hold?

Erez holds options over 10,000 ordinary shares at an exercise price of $11.52, expiring on December 31, 2033, and options over 50,000 ordinary shares at $17.63, expiring on December 28, 2032, according to the filing.

How do the Nano-X Imaging (NNOX) RSU grants to Alroy Erez vest over time?

The filing notes RSU grants of 7,792 and 17,544 units vest quarterly over twelve calendar quarters. They began vesting on December 10, 2024 and December 10, 2025, respectively, with full vesting expected by 2027 and 2028, subject to shares sold for tax.